Testing is available using our Oncopanel multigene NGS panel.
Predictive Testing
The Oncopanel assay can detect mutations in a variety of predictive genes including:
- BRCA1 and BRCA2: Predict response to PARP inhibitor therapy
In addition, the Oncopanel assay can detect mutations in genes associated with inherited breast cancer predisposition, in which case follow-up germline/hereditary testing is recommended (see below).
Hereditary Testing
Hereditary testing is available for patients with mutations associated with an inherited predisposition to the development of ovarian cancer, (see our Hereditary Cancer page for details).